Pfizer to Create Biotech Hub in China


Global pharmaceutical giant Pfizer is set to open a new biotech hub in Hangzhou.

Bloomberg report that the $350 million facility will open by 2018, and will be Pfizer's first biotechnology centre in Asia.

Meanwhile, Reuters suggest that the investment could represent an effort by Pfizer to capture a larger share of China's healthcare market. They estimate that this could be worth $158 billion by 2018.

Pfizer's current research and development facilities are in the USA, with the exception of UK sites in Cambridge and Sandwich.

Related Articles
UK and China sign health deal


News | July 31,2017

Chinese healthcare coming to Wales


News | March 07,2017


Playing Spectrum Sino